. Author manuscript; available in PMC: 2024 May 20.

Published in final edited form as: J Am Coll Cardiol. 2023 Nov 30;83(1):109–279. doi: 10.1016/j.jacc.2023.08.017

TABLE 25.

Recommended Monitoring for Patients Taking Other Antiarrhythmic Drugs

Drug	Baseline Testing	Follow-Up Testing	Additional Follow-Up Testing
Dofetilide	12-lead ECG^* Continuous electrocardiographic monitoring during 3-d hospitalization for dofetilide initiation Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl	In 3-6 mo: 12-lead ECG^* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl	Every 3-6 mo (more frequently for patients concomitantly taking other QT intervalprolonging drugs or with changing kidney function: 12-lead ECG^* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl
Dronedarone	12-lead ECG^* AST^† ALT^†	Within first 6 mo: AST^† ALT^†	–
Ibutilide	12-lead ECG^* Determination of serum potassium and magnesium concentrations and correction of hypokalemia and/or hypomagnesemia is recommended before initiation of the infusion	Continuous electrocardiographic monitoring for assessment of QTc interval duration is recommended for at least 4 h after infusion or until the QTc has returned to baseline to minimize the risk of ibutilide-associated TdP	–
Procainamide	12-lead ECG^* BP	Electrocardiographic monitoring for assessment of rhythm, QRS width and QTc interval is recommended during the infusion to minimize the risk of procainamide-associated ventricular proarrhythmia, including TdP BP monitoring is recommended during the infusion to detect clinically relevant hypotension	–
Sotalol	12-lead ECG^* Continuous electrocardiographic monitoring during 3-d hospitalization for sotalol initiation Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl	In 3-6 mo: 12-lead ECG^* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl	Every 3-6 mo (more frequently for patients concomitantly taking other QT interval-prolonging drugs or with changing kidney function: 12-lead ECG^* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl

Assess rhythm and calculate QTc.

^†

To facilitate early detection of potential dronedarone-associated hepatotoxicity.

ALT indicates alanine transaminase; AST, aspartame transaminase; BP, blood pressure; ECG, electrocardiogram; CrCl, creatinine clearance; and TdP, torsades de pointes.